We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 6
Most popular |Most recent

Senators Grassley and Kohl send another letter to CMS regarding implementation of the Sunshine Act

USA - April 5 2012 Senators Charles Grassley and Herb Kohl have sent a letter to Marilyn Tavenner, Acting Administrator of the Centers for Medicare and Medicaid Services ("CMS"), regarding implementation of the “Transparency Reports and Reporting of Physician Ownership or Investment Interests” section of the Patient Protection and Affordable Care Act (“PPACA”)....

Frank Fazio, Anne E. Wagstaff, Sarah M. Canberg.

Democrats set sights on medical device safety regulation

USA - January 30 2012 Ink-like clouds suffused over our nation’s capitol as a murder of crows converges upon fresh carrion....

Frank Fazio, Anne E. Wagstaff, Sarah M. Canberg.

Zyrtec went viral on YouTube, will others follow?

USA - November 30 2011 With the onset of the fall allergy season, Zyrtec made the bold decision to take its ad campaign viral with an interactive Choose-Your-Own-Adventure style video clip game, Parks Unleashed, on YouTube....

Supreme Court to hear cases on health care reform law

USA - November 21 2011 On November 14th, 2011, the Supreme Court announced in an order that it will hear arguments on three cases from the 11th Circuit challenging the constitutionality of the Patient Protection and Affordable Care Act (“ACA”): National Federation of Independent Business v. Kathleen Sebelius, Secretary of Health and Human Services, et al.; Florida v. Department of Health and Human Services; and Department of Health and Human Services v. Florida....

Frank Fazio, Anne E. Wagstaff, Sarah M. Canberg.

FDA blueprint: gateway, not a barrier to innovation

USA - October 20 2011 In our prior post, “Biotechnology Industry Pushing for Progressive Changes within FDA,” we discussed one industry group’s proposals for changes within FDA aimed at improving and expediting the drug and biologics approval process....